Skip to content
Peptigraph home

VK2735 Phase 2 trial (NCT06828055)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
280
actual
Start
18 Dec 2024 (actual)
Primary completion
24 Jun 2025 (actual)
Sponsor
Viking Therapeutics, Inc.
Design

Arms and doses

NCT06828055 study arms
ArmTypeInterventionsDescription
Placebo AssignmentPlacebo comparatorDrug: PlaceboVK2735 (Placebo) administered Daily
Active Assignment (Dose #1)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #2)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #3)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #4)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #5)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #6)ExperimentalDrug: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Endpoints

Primary endpoint

NCT06828055 primary outcomes
MeasureTime frame
Percent (relative) change from baseline in body weight after 13 weeks of treatment13 Weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06828055 secondary outcomes
MeasureTime frame
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment13 Weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.